Pharmacologic treatments for covid-19 patients

Methods

Protocol

Protocol amendment:

As of March 1, 2022, the COVID-NMA revised its protocol to include only studies evaluating immunomodulators and antiviral therapies. Comparisons evaluating antivirals and immunomodulators will continue to be updated every two weeks.

meta-COVID

Perform your own analysis using COVID-NMA data, create and download your forest plots by clicking below:

go to metacovid

Treatment comparisons

Create and download your forest plots with the most up-to-date data here Forest plots

Access the forest plots for the 315 treatment comparisons .

Search studies

Search by Author Registration number

General characteristics of primary studies

Page: 1 / Sorted by: First Author
Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
Updated
IRCT20201003048904N2
Abbasi F, J Endocr Soc, 2022
Full text
Full text
Commentary
Commentary
Commentary
Public/non profit

Sitagliptin

Spironolactone

Sitagliptin + Spironolactone

Standard care

RCT Patients with suspected or confirmed COVID-19 (unclear severity) admitted to 2 centers in Iran. N=263 N/A

Full description

IRCT20200328046886N1
Abbaspour Kasgari H, J Antimicrob Chemoth, 2020
Full text
Commentary
Public/non profit

Sofosbuvir-Daclatasvir+Ribavirin

Standard care

RCT Patients with confirmed COVID-19 (moderate) admitted to a single center in Iran. N=48
Some concerns
Details

Full description

ISRCTN21085622
Abbass S, J Med Virol, 2021
Full text
Commentary
Private

Sofosbuvir+Daclatasvir

Sofosbuvir + Ravidasvir

Sofosbuvir+Daclatasvir

Sofosbuvir + Ravidasvir

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 4 centers in Egypt N=120
Some concerns
Details

Full description

NCT04345419
Abd-Elsalam S, Am J Trop Med Hyg, 2021
Full text
Commentary
Not reported/unclear

Remdesivir

Standard care

RCT Patients with confirmed COVID-19 (mild-moderate-severe) admitted to two centres in Egypt N=209 N/A

Full description

NCT04353336
Abd-Elsalam S, Am J Trop Med Hyg, 2020
Full text
Commentary
Public/non profit

Hydroxychloroquine

Standard care

RCT Patients with COVID-19 (mild-severe) admitted to three university hospitals in Egypt. N=194
Some concerns
Details

Full description

NCT04447534
Abd-Elsalam S, Biol Trace Elem Res, 2020
Full text
Commentary

Hydroxychloroquine+Zinc

Hydroxychloroquine

RCT Patients with confirmed COVID-19 (mild-critical) admitted to 3 centers in Egypt N=191
Some concerns
Details

Full description

NCT04403555
Abd-Elsalam S, J Med Virol, 2021
Full text
Commentary
Not reported/unclear

Ivermectin

Standard care

RCT Patients with confirmed COVID-19 admitted to 2 centers in Egypt N=164
Some concerns
Details

Full description

NCT04753619
Abdulamir A, Ann Med Surg, 2021
Full text
Full text
Commentary
Commentary
No specific funding

Niclosamide

Standard care

RCT Outpatients and inpatients with confirmed COVID-19 (mild-moderate-severe) admitted or treated by 2 centers in Iraq N=150
Some concerns
Details

Full description

NCT04367168
COLCHIVID
Absalon-Aguilar A, J Gen Intern Med, 2021
Full text
Commentary
Public/non profit

Colchicine

Placebo

RCT Patients with confirmed COVID-19 (severe) admitted to 2 centers in Mexico N=116
Some concerns
Details

Full description

NCT04315948
DisCoVeRy
Ader F, medRxiv, 2022
Full text
Full text
Commentary
Commentary
Commentary
Mixed

Lopinavir-Ritonavir

Lopinavir-Ritonavir+Interferon beta-1a

Hydroxychloroquine

Lopinavir-Ritonavir

Lopinavir-Ritonavir

Lopinavir-Ritonavir+Interferon beta-1a

Hydroxychloroquine

RCT Patients with confirmed COVID-19 (mild-critical) admitted to 32 centers in France and Luxembourg. N=603
Some concerns
Details

Full description